• Foretinib (GSK1363089): Redefining Cancer Drug Response Eval

  2026-07-22

  Discover how Foretinib (GSK1363089) empowers nuanced cancer research by dissecting growth inhibition and cell death with modern in vitro strategies. Explore advanced assay design, mechanistic insights, and practical guidance for translational oncology.

• AZD3463: Mechanistic Insights and Translational Impact in AL

  2026-07-21

  This thought-leadership article explores the mechanistic rationale, validation strategies, and translational significance of AZD3463, a potent ALK/IGF1R inhibitor, for neuroblastoma and ALK-driven cancers. By weaving together evidence from molecular scaffolds, experimental best practices, and the evolving competitive space, the piece delivers actionable guidance for translational researchers seeking to optimize outcomes and overcome resistance in challenging malignancies.

• Dovitinib (TKI-258): Protocol Enhancements for Cancer Resear

  2026-07-21

  Dovitinib (TKI-258) enables robust multitargeted RTK inhibition, advancing apoptosis assays and signal transduction research in complex cancer models. This guide delivers stepwise workflows, troubleshooting insights, and literature-driven protocol optimizations—empowering researchers to achieve reproducible, high-fidelity results.

• Heptamethine Cyanine Dye Suppresses PR in HR+ Breast Cancer

  2026-07-20

  This study introduces CA800-PR, a novel heptamethine cyanine dye, which selectively targets and suppresses the progesterone receptor (PR) in hormone receptor-positive breast cancer cells. The findings highlight a distinctive mechanism involving Golgi fragmentation, offering a promising alternative to conventional hormone therapies and expanding the potential for targeted theranostics.

• Distinct Apoptotic Pathways in BMECs Triggered by C. krusei

  2026-07-20

  This study uncovers how the yeast and hypha phases of Candida krusei induce apoptosis in bovine mammary epithelial cells (BMECs) via separate signaling cascades. These findings provide a mechanistic foundation for understanding mycotic mastitis pathology and offer direction for future apoptosis assay development.

• Preclinical Characterization of Anlotinib: Potent VEGFR2 Inh

  2026-07-19

  This reference study provides a comprehensive preclinical analysis of anlotinib hydrochloride’s high selectivity and nanomolar potency as a multi-target tyrosine kinase inhibitor, especially against VEGFR2. The findings establish anlotinib as a well-tolerated, orally active anti-angiogenic agent, offering significant insights for designing targeted angiogenesis and cancer research assays.

• Network Pharmacology Reveals SFI’s Anti-Glioma Mechanisms vi

  2026-07-18

  This study applies network pharmacology to clarify how Shenqi Fuzheng injection (SFI) inhibits glioma proliferation and migration by targeting the SRC/PI3K/AKT pathway. Integrating computational and experimental approaches, the research identifies shared molecular targets and demonstrates SFI's efficacy in in vitro and in vivo glioma models.

• Cepharanthine Inhibits Endometriosis Growth via Apoptosis an

  2026-07-17

  This study demonstrates that cepharanthine, a biscoclaurine alkaloid, effectively inhibits the growth of endometriosis in vitro, in patient-derived organoid models, and in vivo by inducing apoptosis and impairing DNA repair mechanisms. The findings support cepharanthine's translational potential as a targeted treatment for endometriosis, with implications for disease modeling and apoptosis research.

• Applied Workflows with Tivozanib (AV-951) in Oncology Resear

  2026-07-17

  Tivozanib (AV-951) is setting new standards in anti-angiogenic therapy research, offering unmatched VEGFR selectivity and potency for robust cell-based assays. This guide translates benchmark findings and reference study insights into actionable protocols, advanced troubleshooting, and comparative advantages for precision-driven oncology workflows.

• Dissecting In Vitro Drug Response: Insights from Fractional

  2026-07-16

  Schwartz's dissertation introduces a nuanced analysis of in vitro drug response metrics, distinguishing between relative viability and fractional viability to improve the interpretation of anti-cancer drug efficacy. This work clarifies how these two measures capture different cellular outcomes—growth arrest and cell death—paving the way for more precise evaluation of agents like tyrosine kinase inhibitors in oncology research.

• Epacadostat (INCB024360): Precision Tools for Immunometaboli

  2026-07-16

  Explore the scientific impact of Epacadostat (INCB024360) as a potent IDO1 inhibitor for immuno-oncology research. This article details its mechanistic role in metabolic immune modulation and offers protocol insights grounded in recent standardized assay innovations.

• Gallein: Precision G Protein βγ Subunit Inhibitor Workflows

  2026-07-15

  Gallein enables researchers to dissect and modulate GPCR signaling with unprecedented specificity, unlocking advanced cancer, immunology, and metabolic disease models. This guide details applied workflows, troubleshooting strategies, and innovations stemming from the latest reference studies for robust, reproducible results.

• Pazopanib Hydrochloride: Mechanistic Depth for Translational

  2026-07-15

  Explore how Pazopanib Hydrochloride (GW786034) delivers strategic advantages for translational cancer researchers by uniting mechanistic insight, advanced in vitro protocols, and clinically relevant endpoints. This thought-leadership article synthesizes systems biology, evidence-driven benchmarks, and actionable recommendations to accelerate anti-angiogenic agent development beyond traditional workflows.

• Pazopanib (GW-786034): Applied Workflows for Cancer Research

  2026-07-14

  Pazopanib (GW-786034) empowers cancer researchers to dissect and suppress angiogenesis and tumor growth in genetically defined models, especially those with ATRX deficiency. This article translates recent mechanistic advances and protocol nuances into actionable guidance for maximizing experimental impact with Pazopanib.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Applicati

  2026-07-14

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive, specific detection of goat immunoglobulins in fluorescence-based assays, supporting workflows such as ICC/IF, IHC, flow cytometry, and ELISA. It should be used exclusively with goat primary antibodies and within validated immunodetection protocols; its use outside these boundaries or with non-goat primaries is not supported.

7498 records 12/500 page Previous Next First page 上5页 1112131415 下5页 Last page